Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Buprenorphine | 5 | 2022 | 52 | 1.750 |
Why?
|
| Opioid-Related Disorders | 5 | 2022 | 233 | 1.500 |
Why?
|
| Retinopathy of Prematurity | 4 | 2023 | 75 | 0.930 |
Why?
|
| Laser Coagulation | 3 | 2019 | 55 | 0.820 |
Why?
|
| Bevacizumab | 3 | 2019 | 256 | 0.770 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2019 | 291 | 0.720 |
Why?
|
| Narcotic Antagonists | 3 | 2022 | 170 | 0.700 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2021 | 91 | 0.700 |
Why?
|
| Virtual Reality | 1 | 2021 | 37 | 0.680 |
Why?
|
| Analgesics, Opioid | 5 | 2022 | 513 | 0.650 |
Why?
|
| Naloxone | 2 | 2022 | 72 | 0.630 |
Why?
|
| Fluorescein Angiography | 2 | 2019 | 83 | 0.580 |
Why?
|
| Drug Overdose | 1 | 2019 | 89 | 0.540 |
Why?
|
| Medicare | 1 | 2018 | 455 | 0.440 |
Why?
|
| Cataract | 6 | 2007 | 87 | 0.400 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2022 | 53 | 0.360 |
Why?
|
| Lens Implantation, Intraocular | 3 | 2002 | 24 | 0.340 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 48 | 0.320 |
Why?
|
| Cataract Extraction | 4 | 2007 | 31 | 0.310 |
Why?
|
| Aphakia, Postcataract | 2 | 1999 | 4 | 0.300 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 3110 | 0.280 |
Why?
|
| Visual Acuity | 7 | 2008 | 209 | 0.240 |
Why?
|
| Infant | 13 | 2019 | 3220 | 0.230 |
Why?
|
| Fentanyl | 2 | 2022 | 86 | 0.220 |
Why?
|
| Lens Capsule, Crystalline | 2 | 2002 | 11 | 0.200 |
Why?
|
| Humans | 34 | 2023 | 93515 | 0.200 |
Why?
|
| Ketamine | 1 | 2021 | 26 | 0.180 |
Why?
|
| Methadone | 1 | 2021 | 51 | 0.170 |
Why?
|
| Intravitreal Injections | 2 | 2019 | 83 | 0.170 |
Why?
|
| Female | 21 | 2022 | 48702 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 4 | 1995 | 42 | 0.160 |
Why?
|
| Retrospective Studies | 9 | 2019 | 10164 | 0.160 |
Why?
|
| Biological Products | 1 | 2022 | 178 | 0.160 |
Why?
|
| Child, Preschool | 15 | 2019 | 3829 | 0.150 |
Why?
|
| Cranial Nerve Neoplasms | 3 | 1995 | 12 | 0.150 |
Why?
|
| Optic Nerve Diseases | 3 | 1995 | 16 | 0.150 |
Why?
|
| Barotrauma | 1 | 1999 | 3 | 0.150 |
Why?
|
| Play and Playthings | 1 | 1999 | 7 | 0.150 |
Why?
|
| Carboplatin | 2 | 2018 | 322 | 0.150 |
Why?
|
| Pain | 1 | 2021 | 414 | 0.150 |
Why?
|
| Eye Injuries | 1 | 1999 | 15 | 0.150 |
Why?
|
| Contact Lenses, Extended-Wear | 1 | 1998 | 1 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 2 | 2007 | 245 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2021 | 4560 | 0.130 |
Why?
|
| Retinal Neoplasms | 2 | 2008 | 13 | 0.130 |
Why?
|
| Retinoblastoma | 2 | 2008 | 31 | 0.130 |
Why?
|
| SEER Program | 1 | 2018 | 235 | 0.130 |
Why?
|
| Lens Diseases | 1 | 2017 | 2 | 0.130 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1999 | 114 | 0.130 |
Why?
|
| Eye Infections, Fungal | 1 | 2017 | 13 | 0.130 |
Why?
|
| Candida albicans | 1 | 2017 | 32 | 0.130 |
Why?
|
| Endophthalmitis | 1 | 2017 | 19 | 0.130 |
Why?
|
| Candidiasis | 1 | 2017 | 39 | 0.130 |
Why?
|
| Abscess | 1 | 2017 | 94 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2018 | 479 | 0.120 |
Why?
|
| Lens, Crystalline | 1 | 2017 | 67 | 0.120 |
Why?
|
| Male | 17 | 2021 | 44557 | 0.120 |
Why?
|
| Asthma | 2 | 2022 | 1039 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 590 | 0.120 |
Why?
|
| Incidence | 2 | 2018 | 1701 | 0.120 |
Why?
|
| Recurrence | 1 | 2018 | 1190 | 0.110 |
Why?
|
| Infant, Newborn | 6 | 2023 | 2479 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 579 | 0.110 |
Why?
|
| Algorithms | 1 | 2022 | 1953 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 2544 | 0.100 |
Why?
|
| Infant, Premature | 3 | 2023 | 297 | 0.100 |
Why?
|
| Child | 12 | 2007 | 7355 | 0.100 |
Why?
|
| Eye | 2 | 1984 | 109 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2018 | 3054 | 0.100 |
Why?
|
| Facial Muscles | 1 | 2013 | 24 | 0.100 |
Why?
|
| Eyelids | 1 | 2013 | 24 | 0.100 |
Why?
|
| Oculomotor Muscles | 1 | 2013 | 29 | 0.100 |
Why?
|
| Tendons | 1 | 2013 | 48 | 0.100 |
Why?
|
| Optic Chiasm | 1 | 1992 | 16 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 1992 | 37 | 0.090 |
Why?
|
| United States | 2 | 2019 | 7622 | 0.070 |
Why?
|
| Microphthalmos | 1 | 2008 | 7 | 0.070 |
Why?
|
| Skin Abnormalities | 1 | 2008 | 12 | 0.070 |
Why?
|
| Limb Deformities, Congenital | 1 | 2008 | 19 | 0.070 |
Why?
|
| Laser Therapy | 2 | 2008 | 151 | 0.070 |
Why?
|
| Cryotherapy | 1 | 2008 | 30 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7061 | 0.070 |
Why?
|
| Refraction, Ocular | 2 | 2019 | 11 | 0.070 |
Why?
|
| Podophyllotoxin | 1 | 2007 | 9 | 0.070 |
Why?
|
| Toxoplasmosis, Congenital | 1 | 2007 | 47 | 0.070 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 27 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 100 | 0.070 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 75 | 0.070 |
Why?
|
| Adolescent | 10 | 2008 | 9606 | 0.060 |
Why?
|
| Adult | 7 | 2019 | 27918 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 237 | 0.060 |
Why?
|
| Aged | 4 | 2021 | 20434 | 0.060 |
Why?
|
| Amblyopia | 1 | 2006 | 7 | 0.060 |
Why?
|
| Sensory Deprivation | 1 | 2006 | 32 | 0.060 |
Why?
|
| Eyeglasses | 1 | 2006 | 8 | 0.060 |
Why?
|
| Vitrectomy | 3 | 2003 | 48 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 270 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 641 | 0.050 |
Why?
|
| Eye Diseases | 1 | 1984 | 58 | 0.050 |
Why?
|
| Vision Tests | 1 | 1983 | 20 | 0.050 |
Why?
|
| Vision, Ocular | 1 | 1983 | 73 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 1984 | 166 | 0.050 |
Why?
|
| Retinal Detachment | 1 | 2003 | 60 | 0.050 |
Why?
|
| Administration, Sublingual | 1 | 2022 | 5 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 6 | 0.050 |
Why?
|
| Skin Diseases | 1 | 1984 | 174 | 0.050 |
Why?
|
| Pseudophakia | 2 | 2002 | 3 | 0.050 |
Why?
|
| Gestational Age | 1 | 2023 | 333 | 0.040 |
Why?
|
| Receptors, Opioid, mu | 1 | 2021 | 49 | 0.040 |
Why?
|
| Narcotics | 1 | 2021 | 72 | 0.040 |
Why?
|
| Public Health | 1 | 2022 | 153 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 398 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2007 | 826 | 0.040 |
Why?
|
| Iris Diseases | 1 | 1999 | 5 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2021 | 88 | 0.040 |
Why?
|
| Marfan Syndrome | 1 | 1999 | 27 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 829 | 0.040 |
Why?
|
| Corneal Diseases | 1 | 1999 | 29 | 0.040 |
Why?
|
| Vision, Low | 1 | 2019 | 15 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 8 | 0.040 |
Why?
|
| Injections | 1 | 2019 | 124 | 0.040 |
Why?
|
| Hearing Loss | 1 | 2019 | 64 | 0.040 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 96 | 0.040 |
Why?
|
| Vision, Binocular | 1 | 1998 | 21 | 0.030 |
Why?
|
| Time Factors | 3 | 2019 | 5410 | 0.030 |
Why?
|
| Risk Factors | 3 | 2023 | 5899 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2002 | 3830 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2019 | 237 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 711 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1321 | 0.030 |
Why?
|
| Recovery of Function | 1 | 1999 | 342 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 2017 | 80 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2017 | 122 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 873 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2008 | 9099 | 0.030 |
Why?
|
| Lenses, Intraocular | 1 | 1995 | 8 | 0.030 |
Why?
|
| Syndrome | 2 | 2008 | 437 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 484 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 1995 | 62 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1995 | 86 | 0.030 |
Why?
|
| Age Factors | 4 | 2006 | 1906 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3147 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1914 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1729 | 0.030 |
Why?
|
| Blepharoptosis | 1 | 2013 | 11 | 0.020 |
Why?
|
| Fasciotomy | 1 | 2013 | 19 | 0.020 |
Why?
|
| Theophylline | 1 | 1993 | 34 | 0.020 |
Why?
|
| Cadaver | 1 | 2013 | 199 | 0.020 |
Why?
|
| Glioma | 1 | 1994 | 301 | 0.020 |
Why?
|
| Middle Aged | 3 | 2021 | 27573 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1723 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2008 | 7 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 57 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 759 | 0.020 |
Why?
|
| Pyrimethamine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Sulfadiazine | 1 | 2007 | 23 | 0.020 |
Why?
|
| Blindness | 1 | 2008 | 39 | 0.020 |
Why?
|
| Antiprotozoal Agents | 1 | 2007 | 30 | 0.020 |
Why?
|
| Leucovorin | 1 | 2007 | 200 | 0.020 |
Why?
|
| Etoposide | 1 | 2008 | 204 | 0.020 |
Why?
|
| Ataxia Telangiectasia | 1 | 1984 | 12 | 0.010 |
Why?
|
| Sturge-Weber Syndrome | 1 | 1984 | 9 | 0.010 |
Why?
|
| Pigmentation Disorders | 1 | 1984 | 13 | 0.010 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1984 | 16 | 0.010 |
Why?
|
| Tuberous Sclerosis | 1 | 1984 | 27 | 0.010 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 1984 | 6 | 0.010 |
Why?
|
| Dapsone | 1 | 1984 | 11 | 0.010 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1984 | 18 | 0.010 |
Why?
|
| Ocular Physiological Phenomena | 1 | 1983 | 11 | 0.010 |
Why?
|
| Strabismus | 1 | 1983 | 9 | 0.010 |
Why?
|
| Prednisone | 1 | 1984 | 242 | 0.010 |
Why?
|
| Cats | 1 | 1983 | 285 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 1531 | 0.010 |
Why?
|
| Evoked Potentials, Visual | 1 | 1983 | 90 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2007 | 1006 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1992 | 2585 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1983 | 522 | 0.010 |
Why?
|
| Child Development | 1 | 1983 | 166 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 132 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1448 | 0.010 |
Why?
|
| Visual Cortex | 1 | 1983 | 246 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1992 | 3476 | 0.010 |
Why?
|
| Visual Perception | 1 | 1983 | 334 | 0.010 |
Why?
|
| Miotics | 1 | 1999 | 2 | 0.010 |
Why?
|
| Pilocarpine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Corneal Edema | 1 | 1999 | 5 | 0.010 |
Why?
|
| Aging | 1 | 1983 | 727 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1983 | 2495 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 356 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1993 | 117 | 0.010 |
Why?
|
| Body Temperature | 1 | 1993 | 131 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 401 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 1993 | 110 | 0.010 |
Why?
|
| Fever | 1 | 1993 | 122 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 884 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1994 | 1161 | 0.010 |
Why?
|
| Epiglottis | 1 | 1984 | 6 | 0.000 |
Why?
|
| Complement C3 | 1 | 1984 | 58 | 0.000 |
Why?
|
| Animals | 1 | 1983 | 28155 | 0.000 |
Why?
|
| Mucous Membrane | 1 | 1984 | 82 | 0.000 |
Why?
|
| Basement Membrane | 1 | 1984 | 57 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1984 | 308 | 0.000 |
Why?
|
| Radiography | 1 | 1984 | 790 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1984 | 464 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1984 | 1546 | 0.000 |
Why?
|